Royalty Pharma PLC (RPRX) News & EventsRPRXNews & EventsRoyalty Pharma PLC

Zealand Pharma Enters $100M Royalty Agreement with Royalty Pharma

Zealand Pharma (ZLDPF) announced that it has entered into a royalty purchase and sale agreement with Royalty Pharma (RPRX) in exchange for Zealand Pharma's economics related to rusfertide, a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder. Under the terms of the royalty purchase and sale agreement, Zealand Pharma will receive $100M for the sale of its economic interests related to rusfertide, including rights to one percent royalty on potential future global net sales of rusfertide and regulatory and commercial milestones. Of the $100M, Zealand Pharma will receive an upfront payment of $50M upon closing of the transaction. The remaining $50M is due upon the first anniversary of the closing of the agreement. Zealand Pharma will retain the right to a 0.25% royalty on annual net global sales of rusfertide greater than $1.5B, while Royalty Pharma will retain a 0.75% royalty on sales above $1.5B.

Royalty Pharma Reports 14% Revenue Growth in Q2

"Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%," said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board. "Our transaction pipeline remains exciting and we continued to bolster our development-stage pipeline in recent months, bringing total Capital Deployment to over $1 billion so far in 2026. Following our acquisition of a royalty on AstraZeneca's cliramitug, our development-stage pipeline now totals 19 potential therapies. Lastly, our strong financial performance has allowed us to raise our top-line guidance for the second time this year, driven by the strength of our diversified portfolio. The fundamental tailwinds supporting our business are compelling and we remain well positioned as a premier capital allocator in life sciences to deliver consistent, compounding growth."

Royalty Pharma Acquires Portion of Neurimmune's Royalty for Up to $425M

Royalty Pharma (RPRX) announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's (AZN) cliramitug for up to $425M, including $125M upfront. Cliramitug is a Phase 3 TTR-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy, a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart. Currently approved therapies for ATTR-CM slow disease progression by preventing ATTR accumulation but do not target amyloid already accumulated in the heart. Cliramitug is currently in the Phase 3 DepleTTR-CM trial with results expected in 2028. Under the terms of the agreement, Royalty Pharma will provide Neurimmune up to $425M, including $125M upfront, in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug. In the first quarter of 2027, Royalty Pharma will provide another $125M in cash to Neurimmune, with the remaining $175M payable based on the achievement of certain clinical and regulatory milestones.